Agreement - November 12, 2019
Lytix Biopharma announces a clinical collaboration agreement with Iovance Biotherapeutics
Lytix Biopharma has announced a clinical collaboration with the US-based company Iovance Biotherapeutics to evaluate Lytix’s oncolytic peptide, LTX-315, in combination with Iovance’s T cell therapy. Lytix Biopharma is focused on the development of oncolytic molecules based on research in “host defense peptides”. The company’s lead compound, LTX-315, is administrated intra-tumorally and works by inducing […]
In a new job - June 17, 2019
Nobel Laureate joins Lytix Biopharma’s Scientific Advisory Board
The company announces the addition of Nobel Laureate Dr James Allison and Oncologist Dr Padmanee Sharma from the MD Anderson Cancer Center to its SAB and as Company Strategic Advisors. Dr James (Jim) Allison (PhD) is Regental Professor and Chair of Immunology and Executive Director of Immunotherapy at the MD Anderson Cancer Clinic, University of […]
